A boost for early phase clinical trials
The Charles Wolfson Charitable Trust, a long-standing supporter of Barts Charity, has pledged £1 million to support the development of a new Clinical Research Facility at The Royal London Hospital.
The state-of-the-art facility will expand the range and scale of early phase clinical trials. This could mean earlier access to potentially life-changing treatments for our diverse East London population and better representation in vital research.
This incredible pledge marks the first seven figure gift for the Barts 900 campaign.
Chairman, The Hon Andrew Wolfson said:
“When we were approached about this project, we could immediately see its potential to expand access to early phase clinical research trials whilst also supporting the growth of our local and national life sciences ecosystem. We are delighted to be working with the team at Barts Charity again and look forward to seeing how the Clinical Research Facility helps to drive innovation and new therapies.”
Our gratitude for the ongoing support
Opportunities for patients in East London to take part in potentially life-changing, early phase clinical trials have been limited. But that is set to change. We are grateful for the Trust’s ongoing support that impacts patient care and innovation in healthcare and research.
“The Charles Wolfson Charitable Trust’s exceptionally generous pledge of £1 million towards The Royal London Hospital’s new Clinical Research Facility further demonstrates their continued commitment to improving the health of some of the most underserved communities in London and nationally. On behalf of everyone at Barts Charity and Barts Health NHS Trust, I want to thank the Trustees for believing in our extraordinary mission which will deliver significant health and economic gain for our community, London and the UK.”Fiona Miller Smith, CEO, Barts Charity